Establishing schedules for repeated doses of strontium and for concurrent chemotherapy in hormone-resistant patients with prostate cancer: Measurement of blood and urine strontium levels

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 2, 2005, Pages 138-142

  Ben Yosef, Rami ^a,c   Pelled, Omer ^b   Marko, Rachel ^b   Vexler, Akiva ^a   Teshuva, Avi ^b   German, Uzi ^b   Levita, Moshe ^a   Kol, Rina ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b NUCLEAR RESEARCH CENTER NEGEV   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Blood levels; Chemotherapy; Prostate cancer; Strontium 89; Urine levels

Indexed keywords

GEMCITABINE; GERMANIUM; STRONTIUM 89;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CALCULATION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DEVICE INFECTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG URINE LEVEL; GAMMA SPECTROMETRY; HUMAN; MALE; PLASMA HALF LIFE; PROSTATE CANCER; RADIOACTIVITY; URINALYSIS;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; STRONTIUM RADIOISOTOPES;

EID: 17044387243     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000144728.30492.43     Document Type: Article

References (21)

1. Friedlans J. Local and systemic radiation for palliation of metastatic disease. Urol Clin North Am. 1999;26:391-402.
2. Akerley W, Butera J, Wehbe T, et al. A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer. 2002;94:1654-1660.
3. Sciuto R, Festa A, Rea S, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43:87-88.
4. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet. 2001;357:336-341.
5. Wehbe T, Akerley W, Noto R, et al. Strontium-89, estramustine and vinblastine (SEV) in hormone-refractory prostate carcinoma (HRPC): concurrent chemoradiotherapy. Proc Annu Meet Am Soc Clin Oncol. 1998;17:A1341.
6. Kasalicky J, Krajska V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med. 1998;25:1362-1367.
7. Laing AH, Ackery DM, Bayly RJ, et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol. 1991;64:816-822.
8. Serafini AN. Therapy of metastatic bone pain. J Nucl Med. 2001;42:895-906.
9. Uchiyama M, Narita H, Makino M, et al. Strontium-89 therapy and imaging with bremsstrahlung in bone metastases. Clin Nucl Med. 1997;22:605-609.
10. Baziotis N, Yakoumakis E, Zissimopoulos A, et al. Strontium-89 chloride in the treatment of bone metastases from breast cancer. Oncology. 1998;55:377-381.
11. Blake GM, Zivanovic MA, McEwan AJ, et al. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med. 1986;12:447-454.
12. Breen SL, Powe JE, Porter AT. Dose estimation strontium-89 radiotherapy of metastatic prostate cancer. J Nucl Med. 1992;33:1316-1323.
13. Blake GM, Zivanovic MA, McEwan AJ, et al. Sr-89 radionuclide therapy: dosimetry and hematological toxicity in two patients with metastasizing prostatic carcinoma. Eur J Nucl Med. 1987;13:41-46.
14. Giammarile F, Mognetti T, Blondet C, et al. Bone pain palliation with 85Sr therapy. J Nucl Med. 1999;40:585-590.
15. Ackery D, Yardley J. Radionuclide-targeted therapy for the management of metastatic bone pain. Semin Oncol. 1993;20(suppl 2):27-31.
16. Robinson RG, Blake GM, Preston DF, et al. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics. 1989;9:271-281.
17. Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective randomized double blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 1991;27:954-958.
18. Scmeler K, Bastin K. Strontium 89 for symptomatic metastatic prostate cancer to bone: recommendation for hospice patients. Hospice J. 1996;11:1-10.
19. McEwan AJ, Porter AT, Venner PM, et al. An evaluation of the safety and efficacy of treatment with strontium-89 in patients who have previously received wide field radiotherapy. Antibody Immunoconjugates Radiopharmaceuticals. 1990;3:91-98.
20. Akerley W, Butera J, Wehbe T, et al. A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer. 2002;94:1654-1660.
21. Sciuto R, Festa A, Rea S, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43:79-86.